Jörg Hans, CEO and Managing Director of medac, is retiring after 42 years with the company. Frank Lucaßen, Chief Commercial Officer (CCO) and Managing Director at medac, succeeds him following the realignment of the sales organization.
With more than four decades of service, Jörg Hans has played a key role in shaping the company and has been committed to improving patients' quality of life daily. On October 1, 2023, he will be taking his well-deserved retirement. Jörg Hans leaves behind a remarkable trail of successes that have made the company a leading player in the German pharmaceutical industry.
Jörg Hans has been crucial in making medac a full value-added pharmaceutical company today. He drove the establishment of medac's own production of pharmaceuticals and was Managing Director of medac's production subsidiary Oncotec Pharma Produktion GmbH in Dessau-Roßlau for 16 years. Under his leadership, medac made the leap from trader to producer.
As Jörg Hans' successor, Frank Lucaßen will take over the position as CEO. Frank Lucaßen joined the company ten months ago and, with his experience and expertise as Executive Vice President Northern and Central Europe at Fresenius Kabi AG, has initiated forward-looking changes for medac within a very short time. "My focus for the first few months was on the strategic expansion of markets for our existing products. We will continue to pursue this path in the coming years. My goal is to make our high-quality medicines available to patients worldwide," explained Frank Lucaßen.
Currently, the tasks and responsibilities are being handed over to Frank Lucaßen. This is taking place in intensive contact with medac's employees, customers and stakeholders.
In addition to Frank Lucaßen as CEO and Managing Director for Governance & Support and Commercial Operations, Frank Generotzky will continue to be responsible for Operations and Heiner Will for Marketing, Business Development & Science.
About medac
Since its founding in 1970, medac Gesellschaft für klinische Spezialpräparate mbH has evolved from an oncological niche product distributor to a global player in the pharmaceutical sector. With in-house research, diagnostics, production and foreign subsidiaries, the company expanded its spectrum. The internationalization since 2000, including approvals in the USA and in Japan as well as innovative therapeutics, mark further milestones in medac's success story.
“My focus for the first few months was on the strategic expansion of markets for our existing products. We will continue to pursue this path in the coming years. My goal is to make our high-quality medicines available to patients worldwide.”
Frank Lucaßen, Chief Commercial Officer (CCO) and Managing Director at medac
